FTC/DoJ Revision Of Merger Guidelines Unlikely To Alter Pharma Deals
Executive Summary
The Federal Trade Commission and Department of Justice are revising their guidelines for evaluating whether horizontal mergers are anticompetitive. While they may decide to consider additional factors in their analysis, antitrust lawyers do not expect to see a major change for drug firms
You may also be interested in...
Merger Enforcement: FTC And Justice Department Casting Wide Net In Considering Changes
Agencies seek public comment on how they can modernize merger guidelines to enforce antitrust laws. List of questions, including what types of evidence show that a merger could reduce competition, indicate pharma and other mergers will face greater scrutiny.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials